OXB acknowledges role as Aura's manufacturer for ocular cancer drug bel-sar
The UK contract manufacturer says it will make Aura Biosciences' virus-like drug conjugate for late-stage trials, with a possible route into commercial supply, though terms remain undisclosed.
17 Nov 2026 · OXB · Company news
OXB, the UK contract development and manufacturing organisation focused on cell and gene therapies, said on 17 November 2026 that it has a supply and manufacturing relationship with Aura Biosciences. The company will help produce belzupacap sarotalocan, known as bel-sar, Aura's virus-like drug conjugate for cancers of the eye.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Manufacturing & supplyAll →
Manufacturing & supply
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
18 Nov 2026 · Health Canada · Regulator
Manufacturing & supply
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
18 Nov 2026 · Health Canada · Regulator
Manufacturing & supply
Health Canada: Raz Design recalls shower commode chairs over seats that can break
18 Nov 2026 · Health Canada · Regulator
Manufacturing & supply
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
18 Nov 2026 · Lantern Pharma Inc. LTRN · Company news
Manufacturing & supply
Diagnostica Stago recalls lot of STHEMO DDi M, Dutch inspectorate notice shows
17 Nov 2026 · IGJ · Regulator
Manufacturing & supply
MHRA lists eight device Field Safety Notices in weekly update for 9–13 November
17 Nov 2026 · MHRA alerts · Regulator